Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On July 31, 2014, we and Mayo Clinic entered into an agreement under which Mayo Clinic and the investigator agreed to transfer to us certain data and information from the MF Pilot Study, and agreed that we will assume full responsibility for the investigator's IND, as well as responsibility for the conduct of the MF Pilot Study as the trial sponsor. In September 2014, the investigator's IND, under which the MF Pilot Study has been conducted, was transferred to us and we assumed responsibility for the MF Pilot Study as the trial sponsor. Dr. Tefferi continues as the principal investigator for the trial. As of October 15, 2014, 23 patients out of the 80 patients enrolled in the MF Pilot Study continue to receive imetelstat treatment, which includes 17 out of 62 patients with MF, five out of nine patients with RARS-MDS and one out of nine patients with blast-phase MF. We do not intend to enroll additional patients in the MF Pilot Study. The remaining patients in the MF Pilot Study will continue to receive imetelstat treatment and we will continue to collect data and information from the MF Pilot Study.
The investigator has informed us that he has submitted an abstract for the ASH annual meeting in December 2014 in which he has analyzed certain safety and efficacy data from MF patients in the MF Pilot Study and updated his analysis from the preliminary data he presented in December 2013. In accordance with ASH policies, abstracts submitted to the ASH annual meeting are embargoed from the time of submission. To be eligible for presentation at the ASH annual meeting, information contained in the abstract, as well as additional data and information to be presented at the annual meeting, may not be made public before the abstract has been published/presented in connection with the ASH annual meeting. We have not reviewed or independently analyzed the data selected by the investigator for inclusion in the abstract. Our analyses may result in conclusions that are materially different from the investigator's analyses and therefore additional or updated data should be considered carefully and with caution. Please refer to the risk factor entitled, "Risks Related to Our Business-Success in early clinical trials may not be indicative of results in subsequent clinical trials. Likewise, data reported by investigators from time-to-time is subject to review and verification procedures that could result in material differences to final data and may change as more patient data becomes available." in Part II, Item 1A entitled, "Risk Factors", in this Form 10-Q.
http://biz.yahoo.com/e/141105/gern10-q.html
A million share block traded shortly before two pm and its been a steady climb since then. No specific news that I can find. ASH abstracts late next week.
Also, it is time stamped before noon. If it were valid, it would already have caused a reaction in the stock price.
I don't understand this press release very well, but it seems bogus to me. There is no similar news on Geron's website and the "press release" refers to the "Investigator Sponsored clinical trial", which was at Mayo and which had its hold lifted long ago.
http://seekingalpha.com/article/2463965-geron-best-buy-in-the-market?uprof=45
Geron: Best Buy In The Market
Sep. 2, 2014 2:23 AM ET
Summary
•Geron has the largest potential upside of any stock I follow.
•Recent patient information suggests substantial efficacy in MF and now a third MPN disease after ET, MDS-RARS.
•Acquiring the Mayo Clinic's data and IND is a critical step to move the company forward.
•Many positive catalysts could occur at any time. Sitting on sidelines risks missing those events.
Have we ever heard any follow up on TJ Atchison and the others in that trial?
What kind of human being would say "It was just a war"?
Lee, I cannot reply privately. I deleted the post you asked about myself after having second thoughts about its content. I posted a response to a private message from Basserdan, then decided it is probably best to remain mostly an observer as opposed to a participant in this circus. So I deleted its content.
delete
"Inane political posts, over and over that repeat the same old cliches, the same old tiresome philosophy..."
That's not opinion, but fact... Even if I agreed with the posts, I would find them tiresome...
It seems obvious that Lee is absolutely correct in how he feels and what he thinks he sees. Anyone who cannot see that simply doesn't want to see it, imo. And he's right about politics and that politics should be discussed on a very limited basis here. The only reason I even lurk around here any more is to see Zab regularly put people in their places.
The latest info from about two weeks ago still claims about 25 million shorts, long after the short trade made little sense to me.
http://www.nasdaq.com/symbol/gern/short-interest
And there are a LOT of shorts in this particular stock. Once the price gets up a good head of steam, it's hard to stop.
I didn't put words in anyone's mouth. I asked if that was what he was saying, as hard as it was to believe. And guess what? He said "sure unemployment is welfare"! I have worked all my life and all those years my employer has paid into an unemployment fund. The few weeks that I have been laid off over the last 40 years, I have collected unemployment benefits (after a waiting period). I have paid much more into the fund than I have ever collected. There is no way anyone with any knowledge of how the system works would call unemployment "welfare".
Are you saying that the definition of "being on welfare" includes collecting unemployment benefits? If so, how do you justify such a definition?
I rarely use the "ignore" feature, but you have earned it...
When one posts ignorant drivel, people naturally assume that one is ignorant.
Since you posted that, the implication is that you believe it. If you believe that, you will believe anything...
Lee, of course it depends on what software you are using. I have Microsoft Word 2007. If I have a status bar showing with this software, it can be set to display a running word count which is always visible. If not, click on "Review", "Proofing", then "Word Count", to see the same info. Hope this helps.
Tinner, I agree with much of what you present, but when you make such a seemingly nonsensical statement as this, and then have nothing to say when challenged about its veracity, you lose a great deal of credibility.
That seems to be a problem with many political discussions. People on both sides say whatever they want to validate their point, then their words are picked up by others wanting to make the same or similar talking points, and soon much of the discussion degenerates into meaningless repetition of inaccurate and unverifiable nonsense.
We have great roads, yet I often hear what terrible shape they are in. When I hear that from someone, I immediately ratchet up my skepticism when I consider any statement from the same source.
Such is the nature of political discussion. For the most part, what a waste of time and effort!
Can you explain what you mean by "horrific roads" and tell me where I might find some of these roads on the USA? I live in NC and can get in my car and go about anywhere I want at about 80 miles per hour with almost no problem at all. How could our roads be any better?
It's all about the data. If the trials at Mayo and at Geron produce positive results, FDA approval and a much higher stock price will follow, not necessarily in that order. As investors, our next best chance to learn more about that data may be the AACR 2014 conference in about six weeks. With that in mind, this is from the AACR website...
"PUBLICATION OF ABSTRACTS
To assist attendees in planning their schedule for the meeting, accepted abstract titles will be made available online beginning February 19. Abstract bodies will not be made available online until March 5, one month prior to the meeting. (Late-Breaking Abstracts will be made available on April 4, the day before the start of the meeting.) Abstracts that have been selected for inclusion in the AACR press program will be made publicly available at the date and time of their presentation, either at the meeting or an official AACR press conference."
I hate to say it, but those results are old numbers from the ET study, not the current MF study. But Dr. Tefferi did at least apparently wrap up his presentation with a discussion of Imetelstat. Considering the title of the lecture, that sounds like a positive development.
Hello, Zab, nice to hear from you... Hope all is well...
What bullsh*t!
Research tells me there were about 1596670 cancer diagnoses expected in the US in 2011 and that about 9.5% of those were expected to be myeloid malignancies. A poster on another site claims personal knowledge that a single treatment costs about $50000. Geron's data reflects an average of slightly more than ten treatments so far for each of the 22 patients discussed. If all these best case assumptions are true, and Geron treated all diagnosed myeloid malignancies with Imetelstat, the math works out to slightly more than $75 BILLION per year in revenues. Even if it were to amount to five or ten percent of that, it's still a lot of money.
Up about sixty or seventy cents after hours. What gives?
http://www.businesswire.com/news/rxtimes/20131202005396/en/Asterias-Biotherapeutics-Files-Registration-Statement-Underwritten-Public
December 02, 2013 09:00 AM Eastern Time
Asterias Biotherapeutics, Inc. Files Registration Statement for Underwritten Public Offering
MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that Asterias has filed a registration statement with the Securities and Exchange Commission for an underwritten public offering of up to $15,000,000 of units with each unit consisting of one share of Series B common stock and one redemption right. The shares of Series B common stock and redemption rights will immediately be freely tradable as separate securities. The number of units to be sold and the price range for the proposed offering have not yet been determined.
The offering will be made through Burrill Securities LLC.
Asterias plans to use the net proceeds of the offering to fund its product development programs and for working capital. Asterias intends to apply to list the Series B common stock on the NYSE MKT under the symbol “AST”.
Each redemption right will entitle the holder to sell a share of common stock to Asterias during a redemption period that will commence 30 days prior to the third anniversary of the closing of the offering and that will end on that third anniversary date. If a share is redeemed through the exercise of a redemption right, Asterias will pay the shareholder either an amount of cash, or common shares, no par value, of its parent company BioTime, Inc. (“BioTime”) with a value equal to the initial public offering price of the units, or a combination of cash and BioTime common shares. The decision whether to pay the redemption price in cash or BioTime shares or a combination of cash and shares will be made by Asterias in its discretion. The redemption rights will expire on the earlier of (a) the third anniversary of the closing of the offering, and (b) the earliest date, if any, on which the closing price of the Asterias common stock as reported on a national securities exchange, or the OTC Bulletin Board, has been at least 150% of the redemption price for 10 consecutive trading days.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication does not constitute an offer to sell or a solicitation of an offer to buy these securities; nor shall there be any offer or sale of any of these securities in any State in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering may be obtained, when available, by contacting Robert W. Peabody, Chief Financial Officer, at 510-521-3390, ext. 302 or by email at rpeabody@biotimemail.com.
It sounds a lot like you are saying that the people who are being raked over the coals need to do what they can to protect their interests, and everyone else needs to look the other way.... even hope that they fail...
"...The U.S. effort is expected to include at least 90 Marines and sailors..."
Seems like a pretty puny effort to me. Ninety thousand would probably be a better response, considering the magnitude of the disaster...
"st6ack and schlepp woof" = "stack and schlepp wood" -- only two typos. No problem.
Good morning, my friend.
Hope you're not short...
That's ok. We like shorts under circumstances such as this!
It sure is more fun for the longs when the shorts have to deal with the stock making higher highs.
GERN touching $1.80 per share...
OT I remember him from his playing days. On a sad note, three or four years ago, he was working on his dump truck and his clothes got tangled on the PTO under the truck. He was dead when they found him.
It made good sense to me...
Brightness, would you care to express your opinions, or comment on, this current event?
http://www.latimes.com/entertainment/arts/culture/la-et-cm-mark-rothko-painting-no-1-sells-for-751-million-in-new-york-20121113,0,3205154.story
A highly coveted painting by Mark Rothko has sold for $75.1 million at auction in New York. "No. 1 (Royal Red and Blue)," which the artist created in 1954, didn't break a record, but it did command the second highest price ever for a Rothko, according to Sotheby's.
The auction house had expected the painting to bring in between $35 million and $50 million. The painting had been in the collection of former Sotheby's president John Marion since 1982, according to the Wall Street Journal. The buyer's identity hasn't been disclosed.
And you have whatever it takes for someone like you to broach the subject of politeness. That's rich...
Thanks for the link...